Dronabinol - Ikano Therapeutics

Drug Profile

Dronabinol - Ikano Therapeutics

Alternative Names: Dronabinol intranasal spray

Latest Information Update: 29 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intranasal Therapeutics
  • Developer Ikano Therapeutics
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anorexia; Nausea and vomiting

Most Recent Events

  • 22 May 2009 Preclinical development is ongoing in USA
  • 02 Jun 2006 Preclinical trials in Anorexia in USA (Intranasal)
  • 02 Jun 2006 Preclinical trials in Emesis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top